MEDICUS PHARMA LTD. Financing Cash Flow
MEDICUS PHARMA LTD. (MDCX) reported Financing Cash Flow of $32.35 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- MEDICUS PHARMA LTD. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $25.53M, a 128.84% increase year-over-year.
- MEDICUS PHARMA LTD. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $6.83M, a 81.56% increase year-over-year.
- MEDICUS PHARMA LTD. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $6.65M, a 224.60% increase year-over-year.
- MEDICUS PHARMA LTD. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $10.37M.
- MEDICUS PHARMA LTD. net cash provided by (used in) financing activities for fiscal 2025 was $31.94M, a 151.65% increase from fiscal 2024.
- MEDICUS PHARMA LTD. net cash provided by (used in) financing activities for fiscal 2024 was $12.69M, a 126.24% increase from fiscal 2023.
- MEDICUS PHARMA LTD. net cash provided by (used in) financing activities for fiscal 2023 was $5.61M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $32.35M 10-Q · filed 2026-08-12 | $39.01M derived: sum of 3 quarters · filed 2026-08-12 | $49.38M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $6.83M 10-Q · filed 2026-05-14 | $13.48M derived: sum of 2 quarters · filed 2026-05-14 | $23.85M derived: sum of 3 quarters · filed 2026-05-14 | $35.01M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $6.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $17.02M derived: sum of 2 quarters · filed 2026-03-25 | $28.18M derived: sum of 3 quarters · filed 2026-08-12 | $31.94M 10-K · filed 2026-03-25 |
| 2025-09-30 | $10.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $21.53M derived: sum of 2 quarters · filed 2026-08-12 | $25.29M 10-Q · filed 2025-11-14 | $27.34M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $11.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $14.92M 10-Q · filed 2026-08-12 | $16.96M derived: sum of 3 quarters · filed 2026-08-12 | $16.96M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $3.76M 10-Q · filed 2026-05-14 | $5.81M derived: sum of 2 quarters · filed 2026-05-14 | $5.81M derived: sum of 3 quarters · filed 2026-05-14 | $16.45M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $2.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $2.05M derived: sum of 2 quarters · filed 2026-03-25 | $12.69M derived: sum of 3 quarters · filed 2026-03-25 | $12.69M 10-K · filed 2026-03-25 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $10.64M derived: sum of 2 quarters · filed 2025-11-14 | $10.64M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $10.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $10.64M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $5.61M 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |